Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – March 2011

Pages: 68 Published: March 15, 2011 Report Code: GDPH0211MD

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals March 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the last six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 Pharmaceuticals & Healthcare, Global, Deal Summary 8

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, February 2011 8

2.2 Pharmaceuticals & Healthcare, Global, Top Deals, February 2011 10

2.2.1 Thermo Fisher Scientific Completes Public Offering Of Senior Notes For $2,200 Million 10

2.2.2 Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals 10

2.2.3 Kindred To Acquire RehabCare Group 10

2.2.4 Forest Laboratories To Acquire Clinical Data 10

2.2.5 Steward Health Care Postpones Acquisition Of Jackson Health System 11

2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, February 2011 12

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13

3.1 Pharmaceuticals and Healthcare, Global, M&A, February 2011 13

3.1.1 Top M&A Deals in February 2011 14

3.1.2 Pharmaceuticals and Healthcare, Global M&A Deals by Therapy Area, September 2010 – February 2011 15

3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, February 2011 16

3.2.1 Top Equity Offering Deals in February 2011 17

3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, September 2010 – February 2011 18

3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, February 2011 19

3.3.1 Top Debt Offering Deals in February 2011 20

3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, September 2010 – February 2011 21

3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, February 2011 22

3.4.1 Top PE/VC Deals in February 2011 23

3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, February 2011 24

3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2011 25

3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, September 2010 – February 2011 26

3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, September 2010 – February 2011 27

4 Pharmaceuticals and Healthcare, Global, Partnership Deals, February 2011 28

4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, February 2011 28

4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, September 2010 – February 2011 29

4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2011 30

4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, February 2011 31

4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2010 – February 2011 32

4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), September 2010 – February 2011 33

4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2010 – February 2011 34

5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, February 2011 35

5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, February 2011 35

5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2011 36

5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, February 2011 37

5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, February 2011 37

5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2011 38

5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal values (US$ m), September 2010 – February 2011 39

5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2010 – February 2011 40

5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2010 – February 2011 41

5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2010 – February 2011 42

6 Deal Summary by Therapy Area 43

6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, February 2011 43

6.1.1 Oncology – Deals of the Month 44

6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, February 2011 45

6.2.1 Central Nervous System – Deals of the Month 46

6.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, February 2011 47

6.3.1 Infectious Diseases – Deals of the Month 48

6.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, February 2011 49

6.4.1 Immunology – Deals of the Month 50

6.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, February 2011 51

6.5.1 Metabolic Disorders – Deals of the Month 52

6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, February 2011 53

6.6.1 Cardiovascular – Deals of the Month 54

6.7 Pharmaceuticals and Healthcare, Global, Dermatology Deals, February 2011 55

6.7.1 Dermatology – Deals of the Month 56

7 Deal Summary by Geography 57

7.1 Pharmaceuticals and Healthcare, North America Deals, February 2011 57

7.1.1 North America – Deals of the Month 58

7.2 Pharmaceuticals and Healthcare, Europe, Deals, February 2011 59

7.2.1 Europe – Deals of the Month 60

7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, February 2011 61

7.3.1 Asia-Pacific – Deals of the Month 62

7.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, February 2011 63

7.4.1 Rest of the World – Deals of the Month 64

8 Pharmaceuticals and Healthcare, Top Advisors 65

8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, M&A, September 2010 – February 2011 65

8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2010 – February 2011 66

9 Further Information 67

9.1 Methodology 67

9.2 About GlobalData 67

9.3 Contact Us 68

9.4 Disclosure information 68

9.5 Disclaimer 68

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2010 – February 2011 9

Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, February 2011 10

Table 3: Pharm

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2010 – February 2011 8

Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),February 2011 12

Figure

$1000

Can be used by individual purchaser only

$3000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.